Press Room

Visit our press room for current and past releases about our company.
August 04, 2015

Two Altasciences Executives Named PharmaVOICE 100 Most Inspiring People in the Life-Sciences Industry

Altasciences, a provider of top tier customer-tailored early phase clinical trial services, is pleased to announce that Chris Perkin, CEO at Altasciences, and his colleague, Dr. Brad Vince, CEO and Medical Director at Vince & Associates Clinical Research, an Altasciences company, have been named two of the 100 Most Inspiring People in the Life-Sciences Industry by PharmaVOICE magazine.

July 15, 2015

Dr. Anahita Keyhani Joins Algorithme Pharma Laboratory Leadership as Director, Method Development

Algorithme Pharma, a full service provider focused on early stage clinical research with over twenty years of experience, proudly announces the addition of Dr. Anahita Keyhani to the Algorithme Pharma family.  Dr. Keyhani brings almost two decades of experience to her new role as Director, Method Development, previously Senior Research Scientist at Charles River Laboratories.

March 19, 2015

Algorithme Pharma — Proud Member of the Clinical Data Interchanges Standards Consortium

Algorithme Pharma, an Altasciences company, is now a proud member of the Clinical Data Interchanges Standards Consortium (CDISC), a non-profit organization harmonizing clinical data and streamlining research processes, from protocol through analysis and reporting, including the use of electronic health records to facilitate the collection of high quality research data.

February 19, 2015

CRO Leadership Awards — Altasciences Recognized for Leadership

Altasciences is pleased to announce that its companies, Algorithme Pharma (Montreal, Canada) and Vince & Associates Clinical Research (Kansas, USA), are both 2015 CRO Leadership Award recipients. 

February 10, 2015

Algorithme Pharma USA has its First Studies Underway

Last October, Altasciences expanded into the United States with the opening of Algorithme Pharma USA, in Fargo, North Dakota. Today, we are pleased to announce that our first studies were initiated and completed in January, just 91 days from the US contract being signed, and despite the holiday hustle.